Welcome to our dedicated page for Oruka Therapeutics SEC filings (Ticker: ORKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Oruka Therapeutics Chief Medical Officer Joana Goncalves reported option-related trades and share sales in Oruka Therapeutics, Inc. common stock. On June 15, 2026, she exercised options and warrants to acquire 7,000 shares at exercise prices of $7.80 and $6.84 per share, and sold 7,947 shares in multiple open-market transactions at weighted-average prices around $68–$71 per share.
Following these transactions, she directly held 32,718 shares of common stock. According to the footnotes, some sales were made under a pre-arranged Rule 10b5-1 trading plan entered into on September 19, 2025, and other sales were automatic sell-to-cover transactions to satisfy tax withholding obligations from vesting restricted stock units, indicating a largely routine, pre-planned liquidity and tax-management pattern.
Oruka Therapeutics, Inc.'s Chief Executive Officer Lawrence Otto Klein reported an automatic sale of 1,729 shares of common stock at $69.69 per share. According to the footnote, this was carried out under the company’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding obligations from vesting restricted stock units.
After this tax-related sale, Klein directly holds 925,580 shares of Oruka Therapeutics common stock. Because the transaction was solely to cover taxes and was not discretionary, it functions more like a routine payroll event than an active decision to reduce his investment.
Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler reported an open-market sale of 600 shares of common stock at $69.69 per share. The sale was executed under the company’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding obligations from vested restricted stock units.
After this transaction, Sandler directly holds 236,384 shares of Oruka Therapeutics common stock. The filing reflects a small, tax-driven disposition rather than a discretionary change in her overall ownership stake.
Oruka Therapeutics, Inc. General Counsel Paul T. Quinlan reported an automatic sale of 733 shares of common stock at $69.69 per share. The sale was executed under the company’s non-discretionary sell-to-cover procedure to satisfy tax withholding from restricted stock unit vesting. After this transaction, he holds 31,034 shares directly, so the sale represents a small portion of his ownership and reflects a tax-related mechanism rather than a discretionary trade.
Oruka Therapeutics director Carl Dambkowski reported planned share sales. He sold 22,417 shares of common stock on June 11, 2026 at a weighted average price of $70.1343 per share, followed by 12,583 shares on June 12, 2026 at $70.1090 per share in open-market transactions. According to a footnote, these sales were made under a pre-arranged Rule 10b5-1 trading plan. After the transactions, he directly holds 38,743 Oruka Therapeutics shares.
ORKA filed a notice of proposed sale of 35,000 shares of Common Stock. The filing identifies Morgan Stanley Smith Barney LLC as the broker and lists a 02/14/2024 partnership distribution of 35,000 shares for cash. The excerpt also records a prior 10b5-1 sale by Carl Dambkowski of 105,000 shares on 05/21/2026 for $6,191,367.00.
Oruka Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 2, 2026. Stockholders elected two Class II directors, Lawrence Klein and Chris Martin, to serve until the 2029 annual meeting. Klein received 43,918,579 shares voted for and 63,593 withheld, while Martin received 43,936,173 shares for and 45,999 withheld, with 1,267,194 broker non-votes.
Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026, with 45,206,297 shares for, 39,637 against, and 3,432 abstaining. In a non-binding advisory vote, stockholders approved the compensation of named executive officers, with 43,033,967 shares for, 875,114 against, 73,091 abstaining, and 1,267,194 broker non-votes.
Oruka Therapeutics director Carl Dambkowski received a grant of 9,136 stock options on Common Stock. These options have an exercise price of $55.23 per share and expire on June 1, 2036. The grant was a compensation-related award, bringing his directly held stock options to 9,136. According to the vesting terms, the option vests as to 1/12 of the underlying shares monthly beginning on June 2, 2026, so the award becomes exercisable gradually over time rather than immediately.
Oruka Therapeutics, Inc. director Samarth Kulkarni received a grant of options covering 9,136 shares of common stock. The options have an exercise price of $55.23 per share and expire on June 1, 2036. According to the footnote, the award vests in equal monthly installments over 12 months starting June 2, 2026.
Oruka Therapeutics director Martin Christopher Nathan received a grant of stock options for 9,136 shares of common stock. These options have an exercise price of $55.23 per share and expire on June 1, 2036. The award vests in equal monthly installments over 12 months starting June 2, 2026, aligning the director’s compensation with future company performance.